Respiratory syncytial virus prophylaxis in a tertiary care neonatal intensive care unit.

Abstract

Nosocomial transmission of respiratory syncytial virus (RSV) is a serious, preventable cause of RSV infection. Passive RSV prophylaxis became available in 1996. We compared the RSV nosocomial infection rate in our neonatal intensive care unit before and after RSV prophylaxis, using nosocomial rotavirus infections as a comparator. There were no significant differences between nosocomial RSV infection rates before and after institution of prophylaxis.

• Authors: Ben Z Katz, Christine Sullivan
• Journal: The Pediatric infectious disease journal (Pediatr Infect Dis J) Vol. 28 Issue 9 Pg. 842-4 (Sep 2009) ISSN: 1532-0987 [Electronic] United States
• PMID: 19636282 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antibodies, Viral
• Palivizumab

Topics

• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized
• Antibodies, Viral (therapeutic use)
• Chemoprevention (methods)
• Cross Infection (epidemiology, prevention & control)
• Humans
• Infant
• Infant, Newborn
• Intensive Care, Neonatal
• Palivizumab
• Prevalence
• Respiratory Syncytial Virus Infections (epidemiology, prevention & control)